Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab in the Treatment of Alopecia Areata Patients With an Atopic Background and/or High IgE
NCT05551793Phase 2Recruiting
- Start
- Apr 2023
- Primary completion
- Nov 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in alopecia areata comparing Dupilumab with Placebo (2 arms). Primary endpoint: Severity of Alopecia Tool at Week 48. Started Apr 2023; status: recruiting.
02
Drugs
03
Conditions
alopecia areata
Beyond the preview
Go deeper on NCT05551793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05551793.